Pparγ activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes

Atherosclerosis

Volumn 137, Issue SUPPL., 1998, Pages

  Martin, Geneviève ^a   Schoonjans, Kristina ^a   Staels, Bart ^a   Auwerx, Johan ^a  

^a INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Fatty acids; Gene expression; Lipid metabolism; Nuclear receptors; Peroxisomes; Transcription factors

Indexed keywords

CARRIER PROTEIN; CELL NUCLEUS RECEPTOR; FATTY ACID; GLUCOSE; LIPOPROTEIN LIPASE; LONG CHAIN FATTY ACID COENZYME A LIGASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; CELL RECEPTOR; TRANSCRIPTION FACTOR;

ADIPOCYTE; CONFERENCE PAPER; FATTY ACID METABOLISM; FATTY ACID TRANSPORT; GENE EXPRESSION REGULATION; GLUCOSE HOMEOSTASIS; HUMAN; MUSCLE METABOLISM; NONHUMAN; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; ANIMAL; HOMEOSTASIS; METABOLISM; PHYSIOLOGY; REVIEW;

ADIPOCYTES; ANIMALS; FATTY ACIDS; GLUCOSE; HOMEOSTASIS; HUMANS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

EID: 0032037738     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(97)00315-8     Document Type: Conference Paper

References (69)

1. Barnett AH, Eff C, Leslie RDG, Pyke DA. Diabetes in identical twins: A study of 200 pairs. Diabetologia 1981;20:600-9.
2. Granner DK, O'Brien RM. Molecular physiology and genetics of NIDDM; importance of metabolic staging. Diabetes Care 1992;15:369-95.
3. Brunzell JD, Albers JJ, Chait A, Grundy SM, Groszek E, McDonald GB. Plasma lipoproteins in familial combined hyperlipidemia and monogenic familial hypertriglyceridemia. J Lipid Res 1983;24:147-56.
4. Sniderman AD, Wolfson C, Teng B, Franklin F, Bachorik PS, Kwiterovich PO. Association of hyperapobetalipoproteinemia with endogeneous hypertriglyceridemia and atherosclerosis. Ann Intern Med 1982;97:833-9.
5. DeFronzo RA, Ferrannini E. Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic vascular disease. Diabetes Care 1991;14:173-94.
6. Cabezas MC, de Bruin TWA, de Valk HW, Shoulders CC, Jansen H, Erkelens DW. Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance. J Clin Invest 1993;92:160-8.
7. Arner P. Is familial combined hyperlipidaemia a genetic disorder of adipose tissue. Curr Opin Lipidol 1997;8:89-94.
8. Howard BH, Howard WJ. Dyslipidemia in non insulin-dependent diabetes mellitus. Endocr Rev 1994;15:205-16.
9. Flier JS. The adipocyte: Storage depot or node on the energy information superhighway. Cell 1995;80:15-8.
10. Spiegelman BM, Flier JS. Adipogenesis and obesity: Rounding out the big picture. Cell 1996;87:377-89.
11. Auwerx J, Leroy P, Schoonjans K. Lipoprotein lipase: Recent contributions from molecular biology. Crit Rev Clin Lab Sci 1992;29:243-68.
12. Wang C-S, McConathy WJ, Kloer HU, Alaupovic P. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J Clin Invest 1985;75:384-90.
13. Olivecrona G, Olivecrona T. Triglyceride lipases and atherosclerosis. Curr Opin Lipidol 1995;6:291-305.
14. Zechner R. The tissue-specific expression of lipoprotein lipase: Implications for energy and lipoprotein metabolism. Curr Opin Lipidol 1997;8:77-88.
15. Kamp F, Hamilton JE, Westerhoff HV. Movement of fatty acids, fatty acid analogues, and bile acids across lipid bilayers. Biochemistry 1993;32:11074-86.
16. Schaffer JE, Lodish HF. Expression cloning and characterization of a novel long chain fatty acid transport protein. Cell 1994;79:427-36.
17. Suzuki H, Kawarabayasi Y, Kondo J, et al. Structure and regulation of rat long-chain acyl-CoA synthetase. J Biol Chem 1990;265:8681-5.
18. Ginsberg HN, Le N-A, Goldberg IJ, et al. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins C-III and A-I: Evidence that apolipoprotein C-III inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest 1986;78:1287-95.
19. Ito Y, Azrolan N, O'Connell A, Walsh A, Breslow JL. Hypertriglyceridemia as a result of human apo C-III gene expression in transgenic mice. Science 1990;249:790-3.
20. de Silva HV, Lauer SJ, Wang J, et al. Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E. J Biol Chem 1994;269:2324-35.
21. Maeda N, Li H, Lee D, Oliver P, Quarfordt SH, Osada J. Targeted disruption of the apolipoprotein C-III gene in mice results in hypertriglyceridemia and protection from postprandial hypertriglyceridemia. J Biol Chem 1994;269:23610-6.
22. Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator activated receptor (PPAR) in mediating effects of fibrates and fatty acids on gene expression. J Lipid Res 1996;37:907-25.
23. Schoonjans K, Staels B, Auwerx J. The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1996;1302:93-109.
24. Schoonjans K, Martin G, Staels B, Auwerx J. Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr Opin Lipidol 1997;8:159-66.
25. Osumi T, Wen JK, Hashimoto T. Two cis-acting regulatory elements in the peroxisome proliferator-responsive element enhancer region of rat acyl-CoA oxidase gene. Biochem Biophys Res Commun 1991;175:866-71.
26. Tugwood JD, Isseman I, Anderson RG, Bundell KR, McPheat WL, Green S. The mouse peroxisome proliferator activated receptor recognizes a response element in the 5' flanking sequence of the rat acyl CoA oxidase gene. EMBO J 1992;11:433-9.
27. Gulick T, Cresci S, Caira T, Moore DD, Kelly DP. The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. Proc Natl Acad Sci USA 1994;91:11012-6.
28. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell 1994;79:1147-56.
29. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM. mPPARγ2: Tissue-specific regulator of an adipocyte enhancer. Genes Dev 1994;8:1224-34.
30. Fajas L, Auboeuf D, Raspe E, et al. Organization, promoter analysis and expression of the human PPARy gene. J Biol Chem 1997;272:18779-89.
31. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator-activated receptors: Tissue distribution of PPARα, β and γ in the adult rat. Endocrinology 1995;137:354-66.
32. Auboeuf D, Rieusset J, Fajas L, et al. Tissue distribution and quantification of the expression of PPARs and LXRα in humans: No alterations in adipose tissue of obese and NIDDM patients. Diabetes 1997;48:1319-27.
33. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 1992;358:771-4.
34. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 15-Deoxy-D-12,14 prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell 1995;83:803-12.
35. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehman JM. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 1995;83:813-9.
36. Kliewer SA, Sundseth SS, Jones SA, et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors a and g. Proc Natl Acad Sci USA 1997;94:4318-23.
37. Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors a and d. Proc Natl Acad Sci USA 1997;94:4312-7.
38. Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W. The PPARα-leukotriene B4 pathway to inflammation control. Nature 1996;384:39-43.
39. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for Peroxisome Proliferator-Activated Receptor γ (PPARγ). J Biol Chem 1995;270:12953-6.
40. Zhu Y, Qi C, Korenberg JR, et al. Structural organization of mouse peroxisome proliferator activated receptor γ (mPPARγ) gene: Alternative promoter use and different splicing yield two mPPARg isoforms. Proc Natl Acad Sci USA 1995;92:7921-5.
41. Vidal-Puig A, Jimenez-Linan M, Lowell BB, et al. Regulation of PPARγ gene expression by nutrition and obesity in rodents. J Clin Invest 1996;97:2553-61.
42. Auwerx J, Martin G, Guerre-Millo M, Staels B. Transcription, adipocyte differentiation, and obesity. J Mol Med 1996;74:347-52.
43. Wu Z, Bucher NLR, Farmer SR. Induction of peroxisome proliferator-activated receptor y during the conversion of 3T3 fibroblasts into adipocytes is mediated by C/EBPβ, C/EBPδ, and glucocorticoids. Mol Cell Biol 1996;16:4128-36.
44. Wu Z, Xie Y, Bucher NLR, Farmer SR. Conditional ectopic expression of C/EBPβ in NIH-3T3 cells induces PPARγ and stimulates adipogenesis. Genes Dev 1995;9:2350-63.
45. Tontonoz P, Kim JB, Graves RA, Spiegelman BM. ADD1: A novel helix-loop-helix transcription factor associated with adipocyte determination and differentiation. Mol Cell Biol 1993;13:4753-9.
46. Kim JB, Spiegelman BM. ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism. Genes Dev 1996;10:1096-107.
47. Brown MS, Goldstein JL. The SREBP pathway: Regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 1997;89:331-40.
48. Moller DE, Flier JS. Insulin resistance-mechanisms, syndromes, and implications. New Engl J Med 1991;325:938-48.
49. Flier JS. Syndromes of insulin resistance and mutant insulin. In: De Groot LJ, editor. Endocrinology, vol. 2. Philadelphia: Saunders, 1995:1592-604.
50. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-α: Direct role in obesity-linked insulin resistance. Science 1993;259:87-91.
51. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α- and obesity induced insulin resistance. Science 1996;271:665-8.
52. Auwerx J, Bouillon R, Collen D, Geboers J. Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 1988;8:68-72.
53. Shimomura I, Funahashi T, Takahashi M, et al. Enhanced expression of PAI-1 in visceral fat: Possible contributor to vascular disease in obesity. Nat Med 1996;2:800-3.
54. Landin K, Stigendal L, Eriksson E, et al. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism 1990;39:1044-8.
55. Cohen B, Novick D, Rubinstein M. Modulation of insulin activities by leptin. Science 1996;274:1185-8.
56. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose-fatty acid cycle; its role in insulin sensitivity and metabolic disturbances of diabetes mellitus. Lancet 1961;I:785-9.
57. Boden G, Chen X, Ruiz J, White JV, Rossetti L. Mechanisms of fatty acid-induced inhibition of glucose uptake. J Clin Invest 1994;93:2438-46.
58. De Vos P, Lefebvre AM, Miller SG, et al. Thiazolidinediones repress ob gene expression via activation of PPARγ. J Clin Invest 1996;98:1004-9.
59. Groop LC, Bonadonna RC, Del Prato S. Glucose and free fatty acid metabolism in non-insulin dependent diabetes mellitus: Evidence for multiple sites of insulin resistance. J Clin Invest 1989;84:205-13.
60. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996;45:1661-9.
61. Ferrannini E, Barrett EJ, Bevilacqua S, DeFronzo RA. Effect of fatty acids on glucose production and utilization in man. J Clin Invest 1983;72:1737-47.
62. Boden G, Jadali F, White J, et al. Effects of fat on insulin-stimulated carbohydrate metabolism in normal men. J Clin Invest 1991;88:960-6.
63. Bonadonna RC, Zych K, Boni C, Ferrannini E, DeFronzo RA. Time dependence of the interaction between lipid and glucose in humans. Am J Physiol 1989;257:E49-56.
64. Bevilacqua S, Buzzigoli G, Bonadonna R, et al. Operation of Randle's cycle in patients with NIDDM. Diabetes 1990;39:383-9.
65. Felley CP, Felley EM, van Melle GD, Frascarolo P, Jequier E, Felber J-P. Impairment of glucose disposal by infusion of triglycerides in humans: Role of glycemia. Am J Physiol 1989;256:E747-52.
66. Boden G, Chen X. Effects of fat on glucose uptake and utilization in patients with non-insulin-dependent diabetes. J Clin Invest 1995;96:1261-8.
67. Roden M, Price TB, Perseghin G, et al. Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest 1996;97:2859-65.
68. Wititsuwannakul D, Kim K. Mechanism of palmityl coenzyme A inhibition of liver glycogen synthase. J Biol Chem 1977;252:7812-7.
69. Thiebaud D, DeFronzo RA, Jacot E. Effect of long chain triglyceride infusion on glucose metabolism in man. Metabolism 1982;31:1128-36.